CN101480450A - Pharmaceutical composition for reducing blood sugar and blood fat - Google Patents
Pharmaceutical composition for reducing blood sugar and blood fat Download PDFInfo
- Publication number
- CN101480450A CN101480450A CNA2008102400018A CN200810240001A CN101480450A CN 101480450 A CN101480450 A CN 101480450A CN A2008102400018 A CNA2008102400018 A CN A2008102400018A CN 200810240001 A CN200810240001 A CN 200810240001A CN 101480450 A CN101480450 A CN 101480450A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- calcium
- magnesium
- zinc
- chromium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 60
- 239000008280 blood Substances 0.000 title claims abstract description 60
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 62
- 239000011720 vitamin B Substances 0.000 claims abstract description 62
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 54
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 50
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 50
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000011651 chromium Substances 0.000 claims abstract description 37
- 239000011575 calcium Substances 0.000 claims abstract description 36
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 35
- 235000001465 calcium Nutrition 0.000 claims abstract description 35
- 235000012721 chromium Nutrition 0.000 claims abstract description 35
- 239000011777 magnesium Substances 0.000 claims abstract description 35
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 34
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 34
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 34
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 30
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 30
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 30
- 239000011710 vitamin D Substances 0.000 claims abstract description 30
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 30
- 229940046008 vitamin d Drugs 0.000 claims abstract description 30
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011701 zinc Substances 0.000 claims abstract description 28
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 28
- 239000011669 selenium Substances 0.000 claims abstract description 27
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 26
- 239000011572 manganese Substances 0.000 claims abstract description 26
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 26
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 26
- 239000011718 vitamin C Substances 0.000 claims abstract description 26
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 25
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 25
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 25
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 25
- 239000011733 molybdenum Substances 0.000 claims abstract description 25
- 229940046009 vitamin E Drugs 0.000 claims abstract description 25
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 25
- 239000011709 vitamin E Substances 0.000 claims abstract description 25
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000011591 potassium Substances 0.000 claims abstract description 23
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 23
- 235000007686 potassium Nutrition 0.000 claims abstract description 23
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930003270 Vitamin B Natural products 0.000 claims description 61
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 42
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 37
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 34
- 239000010949 copper Substances 0.000 claims description 28
- 229910052802 copper Inorganic materials 0.000 claims description 27
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 21
- 229940055726 pantothenic acid Drugs 0.000 claims description 21
- 235000019161 pantothenic acid Nutrition 0.000 claims description 21
- 239000011713 pantothenic acid Substances 0.000 claims description 21
- 229960002685 biotin Drugs 0.000 claims description 18
- 235000020958 biotin Nutrition 0.000 claims description 18
- 239000011616 biotin Substances 0.000 claims description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 17
- 229960000304 folic acid Drugs 0.000 claims description 17
- 235000019152 folic acid Nutrition 0.000 claims description 17
- 239000011724 folic acid Substances 0.000 claims description 17
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 14
- 239000011630 iodine Substances 0.000 claims description 14
- 229910052740 iodine Inorganic materials 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 7
- 235000013619 trace mineral Nutrition 0.000 abstract description 52
- 239000011573 trace mineral Substances 0.000 abstract description 52
- 239000000203 mixture Substances 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 11
- 229910052742 iron Inorganic materials 0.000 abstract description 11
- 201000001421 hyperglycemia Diseases 0.000 abstract description 5
- 240000002624 Mespilus germanica Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 229940046001 vitamin b complex Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 43
- 229960005069 calcium Drugs 0.000 description 29
- 229940091250 magnesium supplement Drugs 0.000 description 28
- 239000003925 fat Substances 0.000 description 21
- 229940091258 selenium supplement Drugs 0.000 description 20
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 17
- 229960003975 potassium Drugs 0.000 description 17
- 230000006870 function Effects 0.000 description 13
- -1 lipid peroxide Chemical class 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- 229940087168 alpha tocopherol Drugs 0.000 description 9
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 229960000984 tocofersolan Drugs 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 239000002076 α-tocopherol Substances 0.000 description 9
- 235000004835 α-tocopherol Nutrition 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 8
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 7
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 7
- 235000011086 calcium lactate Nutrition 0.000 description 7
- 239000001527 calcium lactate Substances 0.000 description 7
- 229960002401 calcium lactate Drugs 0.000 description 7
- FWBOFUGDKHMVPI-UHFFFAOYSA-K dicopper;2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O FWBOFUGDKHMVPI-UHFFFAOYSA-K 0.000 description 7
- 229960002413 ferric citrate Drugs 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 235000014872 manganese citrate Nutrition 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 7
- 235000006666 potassium iodate Nutrition 0.000 description 7
- 239000001230 potassium iodate Substances 0.000 description 7
- 229940093930 potassium iodate Drugs 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000018716 sodium selenate Nutrition 0.000 description 7
- 239000011655 sodium selenate Substances 0.000 description 7
- 229960001881 sodium selenate Drugs 0.000 description 7
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 7
- 235000000193 zinc lactate Nutrition 0.000 description 7
- 239000011576 zinc lactate Substances 0.000 description 7
- 229940050168 zinc lactate Drugs 0.000 description 7
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229910000323 aluminium silicate Inorganic materials 0.000 description 6
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000011564 manganese citrate Substances 0.000 description 6
- 229940097206 manganese citrate Drugs 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 5
- 235000015229 magnesium lactate Nutrition 0.000 description 5
- 239000000626 magnesium lactate Substances 0.000 description 5
- 229960004658 magnesium lactate Drugs 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 235000015393 sodium molybdate Nutrition 0.000 description 5
- 239000011684 sodium molybdate Substances 0.000 description 5
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940089653 folic acid 0.3 mg Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229940046374 chromium picolinate Drugs 0.000 description 3
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000004337 magnesium citrate Substances 0.000 description 3
- 229960005336 magnesium citrate Drugs 0.000 description 3
- 235000002538 magnesium citrate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000001508 potassium citrate Substances 0.000 description 3
- 229960002635 potassium citrate Drugs 0.000 description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
- 235000011082 potassium citrates Nutrition 0.000 description 3
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 3
- 235000011085 potassium lactate Nutrition 0.000 description 3
- 239000001521 potassium lactate Substances 0.000 description 3
- 229960001304 potassium lactate Drugs 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- PNNHLULHRSZWPG-UHFFFAOYSA-J 1,5-dihydroxypentan-3-yl phosphate;2,3-dihydroxypropyl phosphate;manganese(2+) Chemical compound [Mn+2].[Mn+2].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O PNNHLULHRSZWPG-UHFFFAOYSA-J 0.000 description 1
- XMLHTAFIAXPIDG-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;manganese(3+) Chemical class [Mn+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XMLHTAFIAXPIDG-UHFFFAOYSA-K 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 108010058254 Steroid 12-alpha-Hydroxylase Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- XSCQURIRMINZIY-UHFFFAOYSA-N [Se].COC(C1=CC=CC=C1)OC#N Chemical compound [Se].COC(C1=CC=CC=C1)OC#N XSCQURIRMINZIY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- UBFWAFZODRGFIF-UHFFFAOYSA-N cyanic acid;selenium Chemical compound [Se].OC#N UBFWAFZODRGFIF-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 description 1
- 229960004652 ferrous carbonate Drugs 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940063755 folic acid 0.1 mg Drugs 0.000 description 1
- 229940083563 folic acid 1 mg Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 235000018348 manganese glycerophosphate Nutrition 0.000 description 1
- 239000011584 manganese glycerophosphate Substances 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 229940093914 potassium sulfate Drugs 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicine composition used for reducing blood sugar and blood fat, which is prepared from medlar, vitamin B complex, vitamin C, vitamin D, vitamin E, macroelement of calcium, potassium and magnesium, and trace elements of zinc, selenium, iron, chromium, cuprum, molybdenum, iodin and manganese. The medicine composition is mainly suitable for people with hyperglycemia and hyperlipemiam, has efficacy for reducing blood sugar and blood fat, and can be used for a long time or used according to a treatment course.
Description
Technical field: the present invention relates to the Medicines and Health Product technical field; Pharmaceutical composition in particular for blood sugar lowering and blood fat.
Background technology: said composition comprises Fructus Lycii, compound vitamin B, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese.
Fructus Lycii be a kind of be food be again the natural Chinese medicine of medicine, liver and kidney tonifying is arranged, nourishing YIN and supplementing blood, replenishing vital essence to improve eyesight, the effect of nourishing the lung to arrest cough is flat tonic thing simply; Ancient Chinese medicine is classified Fructus Lycii as on Chinese medicine product, wherein " book on Chinese herbal medicine converge with speech " to evaluation high especially, think that it has the advantage of tens kinds of Chinese medicines concurrently, claims it: " gas can be filled, and blood can be mended, Yang Kesheng, the moon can be grown, fire can fall, rheumatism can be gone "; Clinical Liver and kidney two void that are mainly used in, the soreness of the waist and knees of asthenia of essence and blood is had a dizzy spell, early whitening of beard and hair, visual deterioration, diseases such as sexual hypofunction; Modern pharmacological research confirms that Fructus Lycii has: 1, blood sugar lowering and blood fat, Fructus Lycii have obvious inhibition cholesterol to raise and have slightly to antiatherogenic effect; 2, the effect of blood sugar lowering and raising carbohydrate tolerance; 3, remove the effect of harmful free radical in the body; 4, strengthen the animal heart, cerebral tissue catalase, the activity of lactic acid dehydrogenase can make superoxide dismutase activity rising in the old human blood, and lipid peroxide content reduces, hematopoietic stem cell is strengthened, have the effect of defying age and stimulation animal growth; 5, the liver protecting effect; 6, the effect of enhance immunity and conciliation immunity; 7, anti-cancer and inhibiting tumor effect; 8, protection reproductive system effect; 9, antimutagenic effect; 10, promote the function of intelligence and improvement memory; 11, resisting fatigue and high temperature resistance effect etc.; The Fructus Lycii nature and flavor are gentle, have many useful value to promoting human physiological metabolism's function.
Vitamin B group participates in body internal protein, fat and sugar metabolism, makes the excitement of brain cell and inhibition be in poised state, and it comprises vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid etc., collaborative in vivo performance physiological action.Vitamin B
1Participate in body internal protein, fat, breakdown of carbohydrates metabolism and anabolism, can show vitamin B1 deficiency during shortage is the various dysbolismus of representative, vitamin B in addition
1Also participate in the neural impulse reaction, keep myocardium normal function, keep normal appetite, gastrointestinal peristalsis and digestive juice secretion etc.; Vitamin B
2Have another name called riboflavin, it is the ingredient of many important coenzyme in the body, participate in intravital substance metabolism, guarantee that vivo oxidation reduction reaction and energy generate, participate in anti-oxidative defense system in the body, mainly show oral cavity reproductive system syndrome, retardation of growth, iron deficiency anemia, moisture dermatitis, minimizing erythropoiesis, the systemic-function that affects the nerves, the vision etc. that reduces during shortage; Nicotiamide claims niacin amide or vitamin PP again, and its physiological function is to participate in the body intracellular metabolic, keeps normal neurological function, and pellagra can take place during shortage in synthesizing of assurance gonadal hormone etc., mainly shows as dermatitis, diarrhoea, dull-witted three big symptoms; Pantothenic acid extensively exists in each organism, participates in metabolic activity widely, and known have 70 plurality of enzymes all to need pantothenic acid to participate in all kinds of biochemical reaction of catalysis body, otherwise just can Metabolic disorder; Biotin also is a kind of vitamin B group, coordinates to participate in the metabolism of human body matter and energy with other vitamin B group, and it is synthetic with nucleic acid, and the compositive relation of gonadal hormone is close, and it also has control poliosis, bareheaded effect; Vitamin B
6Play the coenzyme effect of transaminase, amino acid decarboxylases in vivo, guarantee the metabolism of materials such as aminoacid, glycogen, fatty acid and one carbon unit, nicotinic acid, guarantee the normal propagation of nucleic acid and proteinic synthetic and cell, guarantee homergy with neurotransmitteies such as a hydroxytryptamine, taurine, dopamine, guarantee normal immunologic function, immunity degradation during shortage also can cause neural infringement; Vitamin B
12Participate in nucleic acid in vivo, choline, amino acid whose synthetic and fat and sugared metabolism, to hemopoietic function of bone marrow, the gastrointestinal epithelial cells function, liver function and nervous system myelin functional integrity have certain effect, it is the necessary vitamin of intelligence of bringing into normal play, not only cause dysnoesia if lack, also nutritional anemia can occur, influence is to blood supply in the brain; Folic acid participates in the synthetic of aminoacid and nucleic acid, and and vitamin B
12The common generation that promotes cell is with ripe, and normal cell can not carry out mitosis during shortage, the neurological symptom can occur, as: the loss of memory, depression and dementia etc.;
Vitamin C claims ascorbic acid again, vitamin C and collagen in close relations, the vessel softening effect is not only arranged, and the effect that purifies the blood in addition prevents arteriosclerosis, in cholesterol metabolism, play an important role, can effectively reduce neutral fat, can also promote the absorption of human body, for hemopoietic provides essential raw material ferrum in the food, simultaneously, vitamin C regain one's strength, aspect effect such as allaying tiredness, keeping tensions down emotion is obvious;
Vitamin D is the sterols derivant, and the subcutaneous dehydrocholesterol of human body produces vitamin D through ultraviolet radiation
3, ergosterol produces vitamin D behind ultraviolet radiation
2, the two originates different, the function unanimity, and the importance of vitamin D is to regulate the metabolism of calcium and phosphorus in human nutrition; Vitamin D promotes calcium in little intestinal absorption, the then a large amount of calcium of the D that is deficient in vitamin are discharged by feces, thereby cause the human body calcium deficiency, and rickets can take place the child, become the calcium phosphorus of storing in the human body to exhaust and can cause osteomalacia, modal osteomalacia crowd is anemia of pregnant woman, wet nurse and old people.
Vitamin E is all general designations with the bioactive chromone derivative of alpha-tocopherol, and wherein the activity of alpha-tocopherol is the highest, has antioxidation, avoids the effect of biomembrane generation lipid peroxidation; Stop the effect of LDL oxidation formation, thereby prevent the generation of atherosclerosis and cardiovascular disease; Also have to regulate immunity, slow down aging, inhibition tumor in addition, promote fetal development and reproductive performance to reach the protective effect of nerve and skeleton etc.
Trace element zinc is merged in the biomacromolecule ligand---in protein, nucleic acid, the film (being mainly memebrane protein), generate stable metallic biomacromolecule complex---metalloprotein, metalloproteinase nucleic acid complex etc., at present, known these materials participate in the synthetic and degradation process of carbohydrate, lipid, protein and nucleic acid, and the existence of zinc enzyme is all arranged in six big fermentoids; Zinc also is the essential element of enhance immunity vigor; Zinc can promote that proinsulin is converted into insulin by activating protaminase, and zinc deficiency makes insulin be obstructed in the activity of peripheral tissues, and it is unusual to cause glucose tolerance curve.
Trace element-selenium has obvious reduction serum total cholesterol, triglyceride and lipid peroxide, improves high density lipoprotein, the metabolic effect of superabundant fats in the acceleration bodies; Selenium also has the strong anti-oxidation function, but prevention of cardiac; Anticancer by enhance immunity recognition system removing cancerous cell; Remove and the drainage heavy metal ion, hydrargyrum, methyl mercury, cadmium, lead etc. are had Detoxication; Scarce selenium can make the human insulin secretion reduce, impaired glucose tolerance, and oxidation resistance descends and quickens human senility and intelligence decline.
The major physiological function of trace elements iron is as hemoglobin, Myoglobin, and the ingredient of cytochrome etc. participates in transporting and the Tissue respiration process of the interior oxygen of body; In the conveying of oxygen and electronics, play central role; Contain ferrum in the catalatic structure, and hydrogen peroxide relies on catalatic degraded, hydrogen peroxide is a free radical the most dangerous in the human body; Iron deficiency is common in infant, anemia of pregnant woman and wet nurse, causes iron deficiency anemia, and its cardinal symptom is to have a delicate constitution, and memory weakens, and ability to work descends, and iron deficiency also can exert an influence to other system of human body; As the nervous system iron deficiency, can affect the nerves conduction and make the child occur that intelligence reduces and behavior disorder.
Chromium is insulin " collaborative hormone ", to have the effect of active organochromium compounds " glucose tolerance factor (GTF) " form enhancing insulin, mainly be to keep normal carbohydrate metabolism of body and lipid metabolism, following symptom can occur when not enough: weaken glucose tolerance, increase the weight of hyperglycemia, glucose in urine, hypoglycemia, the circulation of acceleration insulin, reduce Insulin receptor INSR quantity, reduce the insulin binding ability, lose weight, increase fat content, increase vision pressure etc.The chromium of two kinds of valence states of stable existence in the environment, i.e. trivalent chromium and Cr VI, trivalent chromium has physiologically active, uses useful and harmlessly in an amount of scope, and Cr VI is a kind of strong oxidizer, and human body is had toxic and side effects.
Copper is the active component of 30 plurality of enzymes such as lysyl oxidase in the body, cytochrome oxidase, monoamine oxidase, MAO, participates in the redox reaction of cell.When lacking copper, 7 α-hydroxyl enzyme and 12 α-hydroxylase activity that the catalysis cholesterol changes cholic acid into reduce, and cholesterol is synthetic and eliminate minimizing, and cholesterol is discharged and is obstructed, and causes hyperlipemia.Absolute or relative copper lacks can make serum TC, TC level raise, and causes high-cholesterol disease.
Molybdenum is one of micro elements needed by human, and it is the formation element of plurality of enzymes, can help the metabolism of carbohydrate and fat, it participates in removing the murder by poisoning of poisonous aldehydes in the human body, eliminate human free radical, have anticancer, defying age, enhancing immunity and anticariogenic function; Scarce molybdenum can bring out cardiovascular disease, cancer and dental caries.
Iodine is the main synthetic thyroid element that participates in human body, and thyroxinic physiological function is to regulate the organism metabolism level, influences the generation of body heat energy, blood glucose and ketoboidies level, muscle and nervous, many-sided functions such as body weight, intelligence and sexual function; Adult's iodine deficiency can cause thyromegaly.
Manganese participates in the formation of some enzymes in human body, it is the metabolism of involved in sugar and lipid not only, and all works in protein, DNA and RNA are synthetic.
Calcium is the macroelement that body weight for humans is wanted, main two aspects that play a part, the one, constitute sclerous tissueses such as bone tooth, the 2nd, with protein bound or constitute the material of specific function with the form of calcium ion, form in so-called miscible calcium pool and the bone tooth calcium and keep dynamic equilibrium, all cells all need its normal function of calcium competence exertion in the body; Anemia of pregnant woman and wet nurse's calcium deficiency can influence the growth of its body constitution and fetus or infant, and calcium deficiency can cause that also endocrine dysfunction and cell cycle regulation are malfunctioning, and anemia of pregnant woman and wet nurse are owing to physiological characteristics, the Deficiency of Intake of ubiquity calcium.
Potassium participates in the metabolic activity of cell, for the normal activity of some enzyme provides suitable condition, its outstanding effect is to keep the normal irritability of myocardial cell, self-disciplining and conductivity, is regulating acid-base balance, keeps osmotic pressure and keeps the water balance aspect to play an important role; Hypokalemia and hyperkalemia all can produce severe impairment to human body, and the lighter can cause tired, irritated, and weight person can cause arrhythmia, even dead.
Magnesium topmost function in human body is the generation of containment free radical, and free radical is short old and feeble factor, also is the factor that mainly causes birth defect; Another function of magnesium is to bring into play the effect of protection skeleton with calcium and vitamin D, and osteoporosis takes place magnesium deficiency easily, fractures easily; Magnesium is protected heart in addition and is prevented and treated the function etc. of diabetes in addition.
Application contains Fructus Lycii, vitamin B
1, vitamin B
2, vitamin B
6, nicotiamide, pantothenic acid, biotin, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese has been known as the compositions of active component, but with Fructus Lycii, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, the manganese compatibility pharmaceutical composition report as yet that is used for blood sugar lowering and blood fat.
Current medicine that is used for blood sugar lowering and blood fat or health food kind have multiple, but action target spot is few, and the link shortcoming needs perfectly, and has the medicine of side effect more, and cost and price are all very high in addition.
Summary of the invention: in order to overcome the shortcoming and defect of existing blood sugar lowering and hypolipidemic medicine, the purpose of this invention is to provide a kind of compositions, said composition is by the collaborative vitamin B that increases of Fructus Lycii
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese blood sugar lowering and blood fat effect, simultaneously by macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese and vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E, replenish and strengthen the effect of Fructus Lycii blood sugar lowering and blood fat, even chronic administration is also without any side effect; Because the result of broad research, the inventor has found Fructus Lycii and vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese novel combination, this novel combination blood sugar lowering and blood fat have synergy; And singly use Fructus Lycii and compound vitamin B, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese, its effect is all not as good as this compositions; There is not incompatibility in this compositions, have no side effect, and cost is low, thereby constitutes the present invention.
The invention provides the pharmaceutical composition that is used for blood sugar lowering and blood fat, it comprises as the Fructus Lycii of active component and vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese.
Fructus Lycii is that the berry of Solanaceae machaka or dungarunga Fructus Lycii Lycium chinense Mill supplies to use; Ovalize spindle shape, dry finished product slightly is crushed, long 1.5-2cm, diameter 4-8mm, orange red to kermesinus, it is slightly sweet to distinguish the flavor of; Kind is more, and is big with lycium barbarum Lycium darbarum L. fruit, and matter is good to be celebrated; Be distributed in east Asia and Europe, all have all over China wild, more with ground such as Ningxia, Gansu, Qinghai, the Inner Mongol, Shaanxi cultivations; The used Fructus Lycii of the present invention can be with its extract as raw material.
Be used for vitamin B of the present invention
1(VitaminB
1), vitamin B
2(VitaminB
2), nicotiamide (Nicotinamide), pantothenic acid (Pantothenic Acid), biotin (Vitamin H), vitamin B
6(VitaminB
6), vitamin B
12(VitaminB
12), folic acid (Folic Acid), vitamin C (VitaminC), all are water soluble vitamins, do not accumulate in vivo; Vitamin D (VitaminD), vitamin E (VitaminE) are fatsoluble vitamiies, and be useful and harmless by the used dosage of the present invention; Zinc (Zn), selenium (Se), ferrum (Fe), chromium (Cr), copper (Cu), molybdenum (Mo), iodine (I) are micro elements needed by human, and manganese (Mn) is human body possibility essential trace element, and calcium (Ca), potassium (K), magnesium (Mg) are the macroelements of needed by human; Macroelement calcium among the present invention can be selected calcium gluconate for use, calcium acetate, calcium caseinate, calcium chloride, calcium citrate, calcium malate, calcium cirate malate, calcium hydrogen phosphate, dalcium biphosphate, calcium phosphate, calcium sulfate, calcium ascorbate, calcium glycerophosphate, calcium lactate, calcium carbonate etc., macroelement potassium can be selected potassium carbonate for use, potassium chloride, potassium citrate, dipotassium hydrogen phosphate, potassium gluconate, potassium sulfate, potassium glycerinophosphate, potassium lactate etc., macroelement magnesium can be selected magnesium chloride for use, magnesium gluconate, magnesium lactate, magnesium citrate, magnesium hydrogen phosphate, magnesium phosphate, magnesium glycerophosphate, magnesium carbonate etc., trace element zinc can be selected zinc citrate for use, zinc gluconate, zinc acetate, zinc carbonate, zinc oxide, zinc chloride, zinc lactate, zinc sulfate, single zinc methionine etc., trace element-selenium can be selected Selenomethionine for use, methoxybenzyl cyanic acid selenium, the two cyanic acid selenium of phenylene, sodium selenite, selenocarrageenan, selenocysteine, the selenizing methionine, sodium selenate etc., trace elements iron can be selected Ferrous gluconate for use, ferrous lactate, ferric ammonium citrate, iron chloride, ferric citrate, ferrous carbonate, ferrous citrate, ferrous fumarate, heme iron, ferric phrophosphate, protohemin, ferrous succinate, ferrous sulfate etc., trace element chromium can be selected chromium trichloride for use, nicotinic acid chromium, chromium picolinate, trivalent chromiums such as chromium yeast, trace copper can be selected curpic carbonate for use, copper citrate, copper gluconate, copper sulfate etc., trace element molybdenum can be selected ammonium molybdate for use, sodium molybdate etc., trace iodine can be selected potassium iodate etc. for use, trace element manganese can be selected manganese sulfate for use, manganese gluconate, manganese glycerophosphate, manganese chloride, manganese citrates etc. all have professional production factory and supplier.
Compositions of the present invention mainly is applicable to hyperglycemia, people with hyperlipidemia, and by the present invention, the effective dose of Fructus Lycii is for to count 5000-15000mg/ days with whole crude drug, vitamin B
1Effective dose be 0.5-20mg/ days, vitamin B
2Effective dose be 0.5-20mg/ days, the effective dose of nicotiamide is 5-50mg/ days, the effective dose of pantothenic acid is 2-20mg/ days, the effective dose of biotin is 0.01-0.1mg/ days, vitamin B
6Effective dose be 0.5-10mg/ days, vitamin B
12Effective dose be 0.001-0.025mg/ days, the effective dose of folic acid is 0.1-1mg/ days, ascorbic effective dose is 30-500mg/ days, the effective dose of vitamin D is 0.0015-0.01mg/ days, the effective dose of vitamin E (in the alpha-tocopherol equivalent) is 5-150mg α-TE/ days, the effective dose of macroelement calcium is counted 250-1000mg/ days with element calcium, the effective dose of potassium is counted 200-1200mg/ days with element potassium, the effective dose of magnesium is counted 100-300mg/ days with element magnesium, the effective dose of trace element zinc is counted 5-20mg/ days with element zinc, selenic effective dose is counted 0.015-0.1mg/ days with elemental selenium, and the effective dose of ferrum is counted 5-20mg/ days with elemental iron.The effective dose of chromium is counted 0.015-0.15mg/ days with elemental chromium, the effective dose of copper is counted 0.5-1.5mg/ days with elemental copper, molybdenic effective dose is counted 0.02-0.06mg/ days with molybdenum, the effective dose of iodine is counted 0.05-0.2mg/ days with elemental iodine, and the effective dose of manganese is counted 1-3mg/ days with element manganese.
Compositions of the present invention can or directly be taken by following pharmaceutical dosage forms dispenser, for example, oral formulations is (as granule, powder, capsule, ball, sheet, dry syrup, liquid formulation), or food such as food (as cookies), mix and prepare with other known additives, this class additive is for example: carrier, disintegrating agent, slow releasing agent, excipient, filler, covering, binding agent, lubricant, antioxidant, apply agent, coloring agent, correctives, sweeting agent, sucrose succedaneum, nutrition enhancer, flavouring agent, surfactant, plasticizer, the PH regulator, freshener, suspending agent, defoamer, antiseptic, thickening agent, solubilisation aids etc. are prepared or they are added food as functional component or additive by usual way.
By the present invention, Fructus Lycii, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, potassium, magnesium and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, iodine, manganese each component can distinguish preparation, the preparation of each component can be mixed the back when using and use or do not mix simultaneously and use.
Advantage of the present invention be this compositions from too many levels, multisystem, many target spots blood sugar lowering and blood fat, the effect of collaborative performance effect is arranged between the each component, blood sugar lowering and blood fat are had significant effect, sufficient raw, cost is low, and each component has no side effect in the compositions, no incompatibility.
Subordinate list 1 causes diabetic mice blood sugar lowering test effect relatively for this compositions and Fructus Lycii component and vitamin added elements component to alloxan.
Subordinate list 2 causes diabetes model rat blood fat reducing test effect relatively for this compositions and Fructus Lycii component and vitamin added elements component to (STZ).
Relatively tabulate below with reference to embodiment and test implementation example effect and to be described in detail the present invention.
Embodiment 1:
Fructus Lycii 1800mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium picolinate (in trace element chromium) 0.1mg,
Copper citrate (in trace copper) 1mg,
Potassium iodate (in trace iodine) 0.1mg,
Manganese citrate (in trace element manganese) 2mg,
Calcium lactate (in element calcium) 600mg,
Magnesium citrate (in trace element magnesium) 250mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 2:
Fructus Lycii 2500mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 8mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium picolinate (in trace element chromium) 0.08mg,
Copper citrate (in trace copper) 0.8mg,
Molybdic acid is received (in trace element molybdenum) 0.03mg,
Potassium iodate (in trace iodine) 0.1mg,
Manganese citrate (in trace element manganese) 2.5mg,
Calcium lactate (in element calcium) 600mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 3:
Fructus Lycii 2800mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium yeast (in trace element chromium) 0.02mg,
Copper citrate (in trace copper) 0.8mg,
Sodium molybdate (in trace element molybdenum) 0.03mg,
Potassium iodate (in trace iodine) 0.1mg,
Manganese citrate (in trace element manganese) 2mg,
Calcium lactate (in element calcium) 600mg,
Potassium citrate (in trace elements K) 600mg,
Magnesium citrate (in trace element magnesium) 300mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 4:
Fructus Lycii 3200mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Pantothenic acid 8mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium yeast (in trace element chromium) 0.02mg,
Copper citrate (in trace copper) 0.8mg,
Sodium molybdate (in trace element molybdenum) 0.03mg,
Potassium iodate (in trace iodine) 0.1mg
Manganese citrate (in trace element manganese) 2.5mg,
Calcium lactate (in element calcium) 600mg,
Potassium citrate (in trace elements K) 600mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 5:
Fructus Lycii 1000mg,
Vitamin B
10.5mg,
Vitamin B
20.5mg,
Vitamin B
60.5mg,
Folic acid 0.1mg,
Vitamin B
120.001mg,
Nicotiamide 5mg,
Pantothenic acid 2mg,
Biotin 0.01mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 5mg,
Sodium selenate (in trace element-selenium) 0.015mg,
Ferric citrate (in trace elements iron) 5mg,
Chromium yeast (in trace element chromium) 0.015mg,
Copper citrate (in trace copper) 0.5mg,
Sodium molybdate (in trace element molybdenum) 0.02mg,
Potassium iodate (in trace iodine) 0.05mg,
Manganese citrate (in trace element manganese) 1mg,
Calcium lactate (in element calcium) 250mg,
Potassium lactate (in element potassium) 200mg
Magnesium lactate (in element magnesium) 100mg,
Vitamin D 0.0015mg,
Vitamin E (in the alpha-tocopherol equivalent) 5mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 6:
Fructus Lycii 4000mg,
Vitamin B
120mg,
Vitamin B
220mg,
Vitamin B
610mg,
Folic acid 1mg,
Vitamin B
120.025mg,
Nicotiamide 50mg,
Pantothenic acid 20mg,
Biotin 0.1mg,
Vitamin C 500mg,
Zinc lactate (in trace element zinc) 20mg,
Sodium selenate (in trace element-selenium) 0.1mg,
Ferric citrate (in trace elements iron) 20mg,
Chromium yeast (in trace element chromium) 0.15mg,
Copper citrate (in trace copper) 1.5mg,
Sodium molybdate (in trace element molybdenum) 0.06mg,
Potassium iodate (in trace iodine) 0.2mg,
Manganese citrate (in trace element manganese) 3mg,
Calcium lactate (in element calcium) 1000mg,
Potassium lactate (in element potassium) 1200mg
Magnesium lactate (in element magnesium) 300mg,
Vitamin D 0.01mg,
Vitamin E (in the alpha-tocopherol equivalent) 150mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn, serve on 10, withdrew 5, obeyed again 10.
Confirm that through animal experiment this compositions belongs to nontoxic level; The crowd takes and does not also see toxicity.
Embodiment 7: this compositions causes diabetic mice blood sugar lowering test effect relatively with each component to alloxan.
Select 60 of Kunming mouses, male female half and half; Wherein 48 mices are male female half and half, and fasting is after 16 hours, tail vein injection alloxan 70mg/kg
-1, after 72 hours, measure fasting blood sugar, blood glucose value is higher than 16.7mmol/L
-1The person is the hyperglycemia mice, according to blood sugar level the hyperglycemia mice is divided into 4 groups: model control group (B group), and the C group, the D group, the E group, each group of test is pressed 0.2mL/10g
-1Continuous 10 days of body weight gastric infusion, fasting in the 10th day gastric infusion after 7 hours is measured after the administration 1 hour with method, 2 hours blood glucose value; 12 remaining mices, as normal control group (A group), model control group and normal control group irritate stomach once for the equal-volume normal saline every day.
Related data sees attached list 1.
Subordinate list 1: this compositions causes diabetic mice blood sugar lowering test effect relatively with Fructus Lycii component and vitamin added elements component to alloxan:
Embodiment 8: this compositions causes diabetes model rat blood fat reducing test effect relatively with each component to (STZ).
Selecting SD is 48 feeds of male rat high lipid food, press an intraperitoneal injection STZ of 25mg/kg body weight (streptozotocin) after raising for 4 weeks, fasting is after 8 hours after 2 weeks, gavage the 20%D-glucose solution by the 2g/kg body weight, do the oral glucose tolerance test, all 0 and 2 hour blood glucose is respectively greater than 7.0 and the rat of 11.0mmol/L, as diabetes modeling success rat.Modeling success rat is divided into 4 groups at random, 12 every group, is respectively matched group (A group), the B group, C group, D group, test is respectively organized distilled water suspension oral gavage that every day, per os gave checking matter and equivalent once, matched group gives equivalent normal saline filling stomach once every day, in administration 12 week back fasting on the 3rd 10 hours, carotid artery blood sampling, measure T-CHOL respectively, triglyceride, high density lipoprotein, three indexs.
Related data sees attached list 2.
Subordinate list 2: this compositions causes diabetes model rat blood fat reducing test effect relatively with Fructus Lycii component and vitamin added elements component to (STZ):
From table 1, can obviously find out, take this composite preparation and take Fructus Lycii component and vitamin added elements component contrast diabetic mice blood sugar lowering test effect the difference of highly significant is arranged.
From table 2, can obviously find out, take this composite preparation and take Fructus Lycii component and vitamin added elements component contrast high blood lipid model rat blood fat reducing test effect the difference of highly significant is arranged.
Claims (5)
1, a kind of pharmaceutical composition that is used for blood sugar lowering and blood fat is characterized in that it is made by weight ratio by following raw materials according:
Fructus Lycii 5000-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0-0.06mg,
Iodine 0.05-0.2mg,
Manganese 1-3mg,
Calcium 250-1000mg,
Potassium 0-1200mg,
Magnesium 100-300mg,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mga-TE.
2, the pharmaceutical composition that is used for blood sugar lowering and blood fat according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Fructus Lycii 5000-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Iodine 0.05-0.2mg,
Manganese 1-3mg,
Calcium 250-1000mg,
Potassium 0-1200mg,
Magnesium 100-300mg,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mga-TE.
3, the pharmaceutical composition that is used for blood sugar lowering and blood fat according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Fructus Lycii 5000-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Iodine 0.05-0.2mg,
Manganese 1-3mg,
Calcium 250-1000mg,
Potassium 200-1200mg,
Magnesium 100-300mg,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mga-TE.
4, the pharmaceutical composition that is used for blood sugar lowering and blood fat according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Fructus Lycii 5000-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 2-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Iodine 0.05-0.2mg,
Manganese 1-3mg,
Calcium 250-1000mg,
Potassium 200-1200mg,
Magnesium 100-300mg,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mga-TE.
5, the pharmaceutical composition that is used for blood sugar lowering and blood fat according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Fructus Lycii 5000-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 2-20mg,
Biotin 0.01-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Iodine 0.05-0.2mg,
Manganese 1-3mg,
Calcium 250-1000mg,
Potassium 200-1200mg,
Magnesium 100-300mg,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mg a-TE.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008102400018A CN101480450A (en) | 2008-12-15 | 2008-12-15 | Pharmaceutical composition for reducing blood sugar and blood fat |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008102400018A CN101480450A (en) | 2008-12-15 | 2008-12-15 | Pharmaceutical composition for reducing blood sugar and blood fat |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101480450A true CN101480450A (en) | 2009-07-15 |
Family
ID=40877839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008102400018A Pending CN101480450A (en) | 2008-12-15 | 2008-12-15 | Pharmaceutical composition for reducing blood sugar and blood fat |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101480450A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104137992A (en) * | 2014-07-29 | 2014-11-12 | 卞佳林 | Health-care food capable of decreasing blood sugar and preparing method of health-care food |
-
2008
- 2008-12-15 CN CNA2008102400018A patent/CN101480450A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104137992A (en) * | 2014-07-29 | 2014-11-12 | 卞佳林 | Health-care food capable of decreasing blood sugar and preparing method of health-care food |
CN104137992B (en) * | 2014-07-29 | 2015-10-21 | 卞佳林 | A kind of hypoglycemia healthcare food and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101642468A (en) | Pharmaceutical composition for lowering blood glucose and blood lipids | |
CN101601681A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
CN101474304A (en) | Pharmaceutical composition for reducing blood sugar and blood fat | |
CN101474300B (en) | Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes | |
CN101480450A (en) | Pharmaceutical composition for reducing blood sugar and blood fat | |
CN101474307B (en) | Pharmaceutical composition for reducing blood sugar and blood fat | |
CN101474299B (en) | Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes | |
CN101474339B (en) | Pharmaceutical composition for reducing blood sugar | |
CN101574404A (en) | Drug composition for reducing blood fat | |
CN101461868A (en) | Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes | |
CN101584736A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
CN101601683A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat and treatment diabetes | |
CN101628081A (en) | Pharmaceutical composition for lowering blood sugar and blood fat | |
CN101574368A (en) | Drug composition for reducing blood sugar and blood fat | |
CN101474204A (en) | Pharmaceutical composition for reducing blood fat | |
CN101474301A (en) | Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes | |
CN101502590A (en) | Pharmaceutical composition for reducing blood sugar and blood fat | |
CN101579441A (en) | Pharmaceutical composition for lowering blood sugar and blood fat | |
CN101474298A (en) | Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes | |
CN101590145A (en) | The pharmaceutical composition that is used for blood sugar lowering | |
CN101632716A (en) | Pharmaceutical composition for reducing blood glucose | |
CN101601726A (en) | The pharmaceutical composition that is used for blood sugar lowering | |
CN101574434A (en) | Drug composition for reducing blood sugar | |
CN101574403A (en) | Drug composition for reducing blood fat | |
CN101579442A (en) | Pharmaceutical composition for lowering blood sugar and blood fat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090715 |